banner--news.png

RESEARCH & SUPPORT | EDUCATION | GLOBAL AWARENESS

News

 

American Cancer Society Releases Updated Guidelines for Prostate Cancer Early Detection Screening

istockphoto.com

In 2012, the U.S. Preventive Services Task Force (USPSTF) stopped advocating for the use of prostate-specific antigen (PSA) to screen men for prostate cancer. The Task Force discouraged the use of PSA testing, declaring with certainty that "the harms outweigh the benefits." For the last 14 years, the American Urological Association (AUA) and the International Prostate Cancer Foundation (IPCF) have strongly opposed this decision and continued to support the use of PSA screening.

The International Prostate Cancer Foundation believes that, with proper interpretation, the test provides critical information in the diagnosis, treatment, assessment, and monitoring of prostate cancer patients and those at risk of developing prostate cancer.

An estimated 36,320 men in the United States were expected to die from prostate cancer in 2026. Screening and detection are instrumental in overcoming mortality, with survival rates over 90% upon early diagnosis and treatment. Deeming PSA screening unnecessary only complicated the battle against prostate cancer.

On November 12, 2026, the American Cancer Society (ACS) updated its guidelines for the prostate-specific antigen (PSA) blood test. PSA screening is a simple blood test that helps diagnose prostate cancer by assessing the level of prostate-specific antigen in the blood. PSA is a key marker of many prostate diseases. Advocates often suggest pairing PSA screening with a follow-up prostate MRI, biomarker testing, and—if necessary—a biopsy for the most accurate result. With this information, physicians can make informed decisions regarding further medical recommendations and provide thoughtful and thorough patient care.

The updated 2026 American Cancer Society guidelines recommend the following:

  • Average Risk: Men at average risk should be screened with a PSA test every 2 years from ages 50 through 69.

  • Higher Risk: Black men should begin annual PSA screening at age 45 and continue through age 69. Non-Black men with a family history of prostate cancer in a close relative (father, brother, or son) should also begin screening at age 45 and continue through age 69:

    • Every year if a close relative was diagnosed before age 65, or if more than one close relative has had prostate cancer.

    • Every 2 years if only one close relative was diagnosed at age 65 or older.

  • Genetic Risk: Men with inherited gene mutations linked to higher risk (such as BRCA2), or those with a close relative carrying such a mutation, should consult their healthcare provider about when to begin screening and how often to test.

  • Ages 70 to 74: Men in this age range should discuss with their healthcare provider whether continuing screening is right for them. If they choose to continue, testing should occur every 2 years.

  • Ages 75 and Older: The ACS does not recommend routine screening at age 75 or older.

  • Life Expectancy: Screening is not recommended at any age for men with a life expectancy of less than 10 years.